Bear Robotics Bets on Elevator Interoperability With a Strategic Investment in M2MTech
19.4.2023 15:57:00 EEST | Business Wire | Press release
Bear Robotics, a Silicon Valley-based innovator of indoor service robots, is continuing its advancements in the robotics and artificial intelligence space. The tech pioneers just announced a strategic investment to fund its Korea-based partner, M2MTech, which specializes in IoT convergence for smart remote and predictive systems with elevators.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230419005038/en/
Servi Lift provides a reliable delivery experience with its elevator integration, making deliveries in multi-story buildings a breeze. (Photo: Business Wire)
This investment comes as Bear Robotics now extends their world-renowned Servi robot line with a fully integrated elevator delivery robot, Servi Lift, which is capable of completing last-mile deliveries inside of multi-story buildings such as hotels, senior living communities, ghost kitchens, hospitals, corporate campuses, and other high-rise commercial and residential real estate properties. "We believe this investment will truly maximize facility efficiencies and minimize user inconvenience,” commented John Ha, co-founder and Chief Executive Officer of Bear Robotics. “The ELSA convergence platform developed by M2MTech provides strong security, interoperability, and connectivity advantages that will set the stage for us to scale our last-mile mobility solutions.”
In engineering Servi Lift, Bear Robotics sought interoperability as its absolute competitive advantage to be applied with major players in the smart elevator market such as OTIS, TKE, Mitsubishi, KONE, Hyundai and Schindler. With the expansion of urbanization, Bear Robotics is bullish on the “smart city” shift to robot-friendly buildings, enhanced access security, and the penetration of smart elevators in smart buildings with strong linkages between systems. “With the global IoT elevator market forecasted to grow to $64 billion by 2030, it was imperative for us to invest into our close partnership with M2MTech that our engineering teams have built over the last couple of years, and to realize the synergies we believe will advance our last-mile aspirations,” commented Juan Higueros, co-founder and Chief Operating Officer of Bear Robotics. “We are confident that this collaborative approach will generate more efficient operations for many of our existing customers and open a broad array of new opportunities that will place Bear Robotics in a position to be the world’s leading multi-story robot delivery solutions provider.”
100 trials of Servi Lift are reserved for 2023. Broader rollouts are lined up across the world in 2024.
About Bear Robotics
Founded in 2017, Bear Robotics manufactures self-driving indoor robots to assist employees on daily tasks that can ease their workload. The Company’s flagship Servi robots have been deployed in hospitality, healthcare, retail, and real estate venues in North America, Europe, and Asia. For additional information, please visit www.bearrobotics.ai.
About M2MTech
Founded in 2014, M2MTech has developed an open and interoperable platform named ELSA (Elevator Smart Advisor, Elevator Smart Remote Management, Smart Predictive Maintenance System). For additional information, please visit https://m2mtech.co.kr/en/.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230419005038/en/
Contact information
Alison Suzuki
Phone: 1-844-SAY-BEAR
Email:
press@bearrobotics.ai
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 12:47:00 EEST | Press release
Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food products. Within this inspiring premise, Good Food Makers confirms itself as one of the main levers f
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 11:16:00 EEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 09:00:00 EEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 09:00:00 EEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release
Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom